New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:41 EDTARGSArgos says treatment with AGS-003, sunitinib improved expected mRCC survival
Argos Therapeutics announced updated results from a completed phase 2 study highlighting the long-term survival observed in patients treated with sunitinib combined with AGS-003, the company's investigational fully personalized immunotherapy for cancer. Results were presented in a poster presentation at the American Society of Clinical Oncology Annual Meeting on Friday, May 30. According to the results of the study titled "Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib," presented by lead author Asim Amin, MD, PhD, treatment with AGS-003 in combination with sunitinib in an unfavorable risk mRCC patient population, resulted in median progression free survival of 11.2 months and median overall survival of 30.2 months. Based upon recently published findings from the International mRCC Database Consortium, similar risk mRCC patients with a time from diagnosis to treatment of less than one year risk factor have an expected median PFS of 5.7 months and median OS of 14.7 months. In addition, 33% of patients survived for greater than 4.5 years and 23% for more than five years, with two patients remaining in long-term remission for longer than five years following continued dosing with AGS-003. Adverse events associated with the use of AGS-003 were minor with no grade 3 or 4 AEs and no evidence of autoimmunity. "These results showing the potential for AGS-003 to double the expected PFS, OS and extend long-term survival in unfavorable risk mRCC, provide strong support for the ongoing, pivotal ADAPT phase 3 trial. Our goal at Argos is to bring this promising, fully personalized immunotherapy to mRCC patients as quickly as possible to address persistent unmet needs in current standard of care," said Jeff Abbey, CEO and president of Argos Therapeutics.
News For ARGS From The Last 14 Days
Check below for free stories on ARGS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
16:35 EDTARGSArgos Therapeutics presents results from trial of AGS-004
Argos Therapeutics announced that the company has presented data from its research involving AGS-004, the company's investigational fully personalized immunotherapy for HIV, at the International AIDS Society Towards a Cure Symposium that was held at the Victoria University City Convention Centre in Melbourne, Australia. Results were presented by Dr. Irina Tcherepanova, Argos' director of molecular biology, in a poster titled "Impact of RNA loaded Dendritic cell immunotherapy on HIV sequence Evolution in Chronic HIV Subjects Undergoing ATI," on Saturday, July 19, from 4:35 6:00 PM. Previously, Argos reported results of a Phase 2a clinical trial designed to assess the impact of AGS-004 during a 12-week ART analytical treatment interruption in chronic HIV-1-infected subjects. In this follow-up sub-study, results presented revealed how viral protein sequences evolve in response to AGS-004-induced immune pressure, and that viral load control was associated with low viral sequence divergence. "To our knowledge this is the first report associating HIV antigen sequence divergence in response to autologous therapeutic immunization with durability of VL control. These results further illustrate the potential for AGS-004 and we are looking forward to additional research milestones later this year," said Charles Nicolette, Argos' chief scientific officer and VP of research and development. This is the first analysis aimed at understanding the effects of AGS-004-induced immune pressure in HIV subjects on viral evolution and diversity. AGS-004 is being further evaluated in a double-blind placebo-controlled phase 2b clinical trial and the company plans to announce initial results from this trial in the coming months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use